

A potential pro-angiogenic cell therapy with human placenta-derived mesenchymal cells

Toshihide Nishishita^{a,*}, Kunie Ouchi^a, Xiaohong Zhang^a, Mariko Inoue^a,
Takeshi Inazawa^a, Kenta Yoshiura^a, Koichiro Kuwabara^a, Takashi Nakaoka^a,
Nobukazu Watanabe^b, Koichi Igura^b, Tsuneo A. Takahashi^b, Naohide Yamashita^a

^a Department of Advanced Medical Science, Institute of Medical Science, University of Tokyo, Tokyo, Japan

^b Division of Cell Processing, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Received 22 September 2004

Abstract

Recently several strategies to treat ischemic diseases have been proposed but the ideal way has to be determined. We explored whether human placenta-derived mesenchymal cells (hPDMCs) can be used for this purpose because placenta is very rich in vessels. First, production of human vascular endothelial growth factor (hVEGF) from hPDMCs was examined. The amount of hVEGF secreted by hPDMCs was similar to the amount produced by HeLa cells. hVEGF was barely detected in human umbilical vein endothelial cells (hUVECs) or human peripheral blood mononuclear cells. hVEGF secreted from hPDMCs stimulated the proliferation of hUVECs, indicating its biological activity. Transplantation of hPDMCs to the ischemic limbs of NOD/Shi-scid mice significantly improved the blood flow of the affected limbs. Blood vessel formation was more prominently observed in the limbs of treated mice as compared to the control mice. Real-time RT-PCR revealed that hPDMCs produced hVEGF for at least 7 days after transplantation. Thus, transplantation of hPDMCs could potentially be a promising treatment for human ischemic diseases.

© 2004 Elsevier Inc. All rights reserved.

Keywords: Angiogenesis; Vascular endothelial growth factor; Cell Therapy; Atherosclerosis

The discovery of potent angiogenic regulators has led to the development of pro-angiogenic therapies for ischemic diseases [1]. Angiogenic factors can be applied to ischemic lesions by direct injection or expression of the gene by plasmid or virus vectors [2–6]. However, the efficacy of these therapies is not always satisfactory. For example, vascular endothelial growth factor (VEGF) gene therapy causes edema and hemangioma due to unregulated gene expression [7,8]. To overcome the shortcomings of single angiogenic factor therapies, the combination of two angiogenic factors has been tested as a treatment for ischemic diseases. These combination therapies are effective in inducing functional and stable

vascular networks [9–11]. Alternatively, delivery of VEGF, when maintained below a threshold microenvironmental level, can lead to normal angiogenesis without other exogenous growth factors [12]. Along with the application of angiogenic factors, cell therapies for ischemic diseases using peripheral blood-derived endothelial progenitor cells [13,14], cord blood-derived endothelial precursor cells [15], peripheral blood mononuclear cells [16], or bone marrow mononuclear cells [17,18] have been reported. Clinical studies of the transplantation of bone marrow mononuclear cells or peripheral blood mononuclear cells have also been performed and the effectiveness in patients has been demonstrated [19]. VEGF and basic fibroblast growth factor (bFGF) produced by mononuclear cells or the transplanted cells are implicated for clinical efficacy, although the exact

* Corresponding author. Fax: +81 3 5449 5456.

E-mail address: tnishi-tyk@umin.ac.jp (T. Nishishita).

mechanism has not been fully elucidated. The collection procedures used for these cell therapies do put the patient at some risk. To collect an adequate number of bone marrow cells, systemic anesthesia is required. In the case of sampling peripheral blood mononuclear cells, leukapheresis is necessary.

Since the establishment of cord blood banks, umbilical cord blood is being frequently used for hematopoietic stem cell transplantation [20]. When cord blood is collected, the adjacent placenta is discarded as medical waste. The placenta contains a large amount of vessels, which are created in a short period of time. Placental cells can be obtained from normal full-term deliveries and banked with HLA typing. It is possible that placenta cells may become a promising resource for cell therapy.

In this study, we used human placenta-derived mesenchymal cells (hPDMCs), which were $CD34^-CD45^-SH2^+SH3^+$ [21]. We examined whether hPDMCs produced angiogenic factors and whether transplantation of these cells could improve blood flow in a hindlimb ischemia model of NOD/Shi-scid mice.

Methods

Reagents. Dulbecco's modified Eagle's medium (DMEM), penicillin–streptomycin–amphotericin B solution, trypsin, and EDTA were purchased from Invitrogen (Carlsbad, CA). RPMI 1640 medium was purchased from Sigma–Aldrich (Munich, Germany), phosphate-buffered saline (PBS) was purchased from Nissui (Tokyo, Japan), and fetal bovine serum (FBS) was purchased from Thermo Trace (Melbourne, Australia). Human umbilical vein endothelial cells (hUEVCs) and endothelial growth medium (EGM) were purchased from Clonetics (San Diego, CA). HeLa cells were provided by Riken (Tokyo, Japan). Recombinant hVEGF and anti-human VEGF blocking antibody was purchased from R&D Systems (Minneapolis, MN). Ficoll–Hypaque was purchased from Amersham (Uppsala, Sweden). Biotinylated anti-rabbit IgG was purchased from Biosource International (Camarillo, CA). Anti-factor VIII polyclonal antibody was purchased from DakoCytomation (Copenhagen, Denmark).

Isolation of hPDMCs. Human placentas were harvested from full-term deliveries (38–40 weeks of pregnancy) and cell processing was started within 4 h of delivery. The use of human placenta was approved by the Ethics Committee of the Institute of Medical Science, University of Tokyo. After removal of the umbilical cord and amnion from the placenta, small pieces of tissues were cut out of maternal part of placenta (decidua). Tissues were chopped with scissors, washed in PBS, and then stirred in PBS with 0.05% trypsin and 0.53 mmol/L EDTA at ambient temperature for 10 min. After being filtered through nylon mesh, FBS (15 mL) was added and the fractions containing the released cells were pooled. The tissue sections were digested 2 more times, and the 3 fractions were mixed. The cells were centrifuged at low speed (1000 rpm for 10 min) and were suspended in PBS. Following flotation on Ficoll–Hypaque, the mononuclear cell fraction was isolated and washed in PBS. Then, the collected cells were seeded at a density of 3.0×10^6 cells/cm² in DMEM with 10% FBS. Ten days after trypsin digestion, adherent and non-adherent cells were harvested with 1 mmol/L EDTA solution. $CD34^-CD45^-SH2^+$ cells were sorted as hPDMCs using a FACS (Vantage SE, Becton–Dickinson). hPDMCs used in this study were within 25 population doubling levels. Surface marker analysis of hPDMCs revealed that they were positive to CD105

and CD73 antibodies and negative to CD14, CD21, CD23, and CD86 antibodies. Chimerism assay showed that hPDMCs are of maternal origin (data not shown).

Cell culture. The cells were grown at 37 °C in an atmosphere of 95% air and 5% CO₂. Antibiotic–antimycotic (1%) was added to all media. hPDMCs (PL26, PL54C, and PL78C) isolated from 3 independent placenta donors were used in this study. hPDMCs were maintained in DMEM with 10% FBS. hPDMCs were routinely passaged just before reaching confluence by brief exposure to 0.05% trypsin and 0.53 mmol/L EDTA at a ratio of 1:8. hUEVCs were grown in EGM containing 2% FBS. HeLa cells were maintained in DMEM with 10% FBS. PBMCs were isolated from human peripheral blood using Ficoll–Hypaque and cultured in RPMI 1640 with 10% FBS. PBMCs-1 and PBMCs-2 were obtained from 2 healthy volunteers (a 40-year-old male and a 42-year-old male).

Assays for hVEGF and other angiogenic factors. To study hVEGF production, fresh culture medium was added when cells reached 80% confluence in 10-cm culture dishes. After 24 h the culture medium was collected and centrifuged at 1000 rpm for 10 min. The supernatant was frozen until assayed. Cultured cells were detached from culture dishes using 0.05% trypsin and 0.53 mmol/L EDTA. Cells were resuspended in 1 mL PBS and the cell number was counted. Recovered cells were subjected to 3 cycles of freeze and thaw. After centrifugation at 2000 rpm for 10 min the supernatant was collected and frozen until intracellular hVEGF content was assayed. hVEGF concentration was measured by ELISA using the Quantikine hVEGF immunoassay kit (R&D Systems, Minneapolis, MN). The detection range of this kit was 5–2000 pg/mL hVEGF. hVEGF concentration was normalized by dividing by the cell number. Triplicate experiments were performed. Data are expressed as means \pm SE. TNF- α (QuantiGlo human TNF- α immunoassay), PlGF (Quantikine human PlGF immunoassay), EGF (Quantikine human EGF immunoassay), b-FGF (Quantikine human basic FGF, R&D Systems, Minneapolis, MN), and HGF (Ohtsuka ELISA kit, Ohtsuka Japan) were also measured.

Thymidine uptake. Thymidine uptake by hUEVCs was examined as described by Conn et al. [22]. hPDMCs were cultured in serum-free DMEM for 48 h. Then the hPDMC culture medium was collected and condensed (by 25 times) using Centriplus YM-10 (Millipore, Bedford, MA). hUEVCs (1×10^6 cells/mL) were seeded into 24-well culture dishes. After 48 h, condensed hPDMC conditioned medium or recombinant hVEGF was added to the culture medium of hUEVCs. Uptake of ³H was measured after 48 h. Triplicate experiments were performed. Data are expressed as means \pm SE.

Mouse hindlimb ischemia model and cell transplantation. NOD/Shi-scid mice were supplied by Nihon Clare (Tokyo, Japan). All animal experiments were performed in the animal research center, observing the guidelines for animal experiments of the Institute of Medical Science, University of Tokyo.

Mice were anesthetized with xylazine 15 mg/kg (i.m.) and ketamine 90 mg/kg (i.p.). Ischemia was induced by ligating the femoral artery and vein of one hind limb beneath the inguinal ligament [23]. Seven days after surgery, ischemia of the limb was evaluated. Mice were anesthetized, and the blood flow in each limb was measured on the sole of the foot using a laser doppler imaging system (Moor Instruments, Sussex UK). Mice with incomplete ischemia (blood flow greater than 30% of the normal limb) were discarded. Mice with decreased blood flow (less than 750 arbitrary flow units) in the normal hind limb were also discarded. Selected mice were systemically irradiated with 1 Gy of gamma ray and received anti-asialo GM1 antiserum to reduce the rejection of transplanted cells [24]. After this procedure 1×10^6 hPDMCs suspended in 0.1 mL medium were injected into ischemic limbs. Injection was divided into 5 or 6 sites on the ischemic limb.

Seven days after and 14 days after hPDMC transplantation we measured the blood flow of the ischemic and non-ischemic limbs. After blood flow was scanned, stored images were subjected to computer-assisted quantification, and the ratios of average flows of ischemic and non-ischemic limbs were calculated.

Immunohistochemistry. To study the new vessel formation after hPDMC transplantation, ischemic adductor muscles were dissected after measurement of blood flow. They were fixed with formalin and embedded in paraffin. Paraffin-embedded sections were then stained with anti-factor VIII antibody [25], followed by secondary antibody reaction and visualized using Dako EnVision plus and Dako DAB substrate kit (DakoCytomation, Copenhagen, Denmark). The capillaries in randomly chosen fields were counted. The number of capillaries was divided by the number of muscle fibers, and this ratio was compared.

Real-time RT-PCR. Primers were designed to amplify the 3' untranslated region of hVEGF cDNA (GenBank:AF022375) so that only VEGF-A mRNA would be detected by RT-PCR. The sequences of the primers were hVL1: GGTCCCTCTTGGAATTGGAT and hVR1: TGTATGTGGGTGGGTGTGTC. The expected PCR fragment length was 115 base pairs. Total RNA was extracted from the adductor muscles of NOD/Shi-scid mice with Tri-zol (Invitrogen, Carlsbad, CA). Five micrograms of total RNA was reverse transcribed with ThermoScript (Invitrogen, Carlsbad, CA) for 1 h at 50 °C. The product was then subjected to the following PCR conditions (Quant-iTect SYBR Green PCR kit, Qiagen, Hilden, Germany): 95 °C for 15 min, 94 °C for 30 s, 56 °C for 30 s, and 72 °C for 30 s (34 cycles), followed by 72 °C for 7 min (iCycler, Bio-RAD, Hercules, CA).

Statistical analysis. The non-parametric Mann–Whitney *U* test was used to evaluate the statistical significance of differences between two groups. *P* values less than 0.05 were considered statistically significant.

Results

hVEGF production by hPDMCs

hVEGF production by various types of cells is presented in Table 1. Data were normalized by dividing the hVEGF concentration by the cell number. HeLa cells were used as a positive control [26]. hPDMCs (PL26, PL54C, and PL78C) and HeLa cells produced hVEGF, and hVEGF concentrations in the media of

Table 1
ELISA of hVEGF

Cell	hVEGF/per 10 ⁴ cells (pg/mL)
<i>hVEGF concentration in the medium</i>	
HeLa	2.50 ± 0.24 (mean ± SE)
PL26	3.58 ± 0.26
PL54C	1.52 ± 0.20
PL78C	0.47 ± 0.05
PBMCs-1	0.0194 ± 0.0022
PBMCs-2	0.0008 ± 0.0004
hUVECs	n.d. ^a
EGM (medium alone)	n.d. ^a
DMEM + 10%FBS	n.d. ^a
<i>Intracellular hVEGF content</i>	
HeLa	1.00 ± 0.13
PL26	0.36 ± 0.06
PL54C	0.33 ± 0.06
PL78C	0.22 ± 0.02
PBMCs-1	0.0022 ± 0.0013
PBMCs-2	0.0048 ± 0.0005
hUVECs	n.d. ^a

^a Not detected.

hPDMCs were similar to those of HeLa cells. In contrast, the hVEGF concentration was very low in the culture media of PBMCs and it was undetectable in the culture media of hUVECs. Considerable amounts of intracellular hVEGF were detected in hPDMCs and HeLa cells. However, only a very small amount of intracellular hVEGF was detected in PBMCs, and intracellular hVEGF was not detected in hUVECs. These results were confirmed in 3 other experiments. Other angiogenic factors (HGF, EGF, PlGF, and TNF-α) were not detected in the supernatant of hPDMCs (data not shown).

Biological activity of hVEGF produced by hPDMCs

To test the biological activity of hVEGF produced by hPDMCs, the proliferation of hUVECs was examined. Application of recombinant hVEGF increased the thymidine incorporation in hUVECs in a dose-dependent manner. Twenty-five times condensed conditioned medium from hPDMCs also increased thymidine uptake, whereas condensed DMEM did not increase thymidine uptake (Fig. 1). The hVEGF concentration in the condensed conditioned medium was 5400 pg/mL (measured by ELISA). The conditioned medium (50 μL) was added




Fig. 1. Thymidine uptake of hUVECs stimulated by recombinant hVEGF. The ordinate indicates the counts of thymidine uptake by hUVECs. Data are expressed as means ± SE (*n* = 4). Left six bars show the counts of thymidine uptake, at different concentrations of recombinant hVEGF. "Culture medium" indicates thymidine uptake of hUVECs stimulated by the condensed hPDMC culture medium. "Control" indicates the condensed DMEM. "Ab" indicates that anti-human VEGF blocking antibody was added to the conditioned medium.

to the hUVEC culture medium (450 μ L), so that the final hVEGF concentration was approximately 0.54 ng/mL. Judging from Fig. 1, the thymidine incorporation induced by the hPDMC conditioned medium was the same as the level induced by 10 ng/mL recombinant hVEGF. A similar result was obtained in 2 other experiments. Thus, the biological activity of hPDMC conditioned medium appeared to be stronger than that predicted by the hVEGF concentration determined by ELISA. When 0.4 μ g/mL anti-VEGF blocking antibody was added with 10 ng/mL recombinant VEGF, it completely blocked the bioactivity. Whereas anti-VEGF blocking antibody only partially blocked the bioactivity of condensed hPDMC conditioned medium.

Improvement of hindlimb ischemia by hPDMC transplantation in NOD/Shi-scid mice

We transplanted hPDMCs into ischemic hindlimbs of NOD/Shi-scid mice to examine whether hPDMCs improved ischemia in vivo. Representative results of blood flow changes in ischemic limbs are shown in Fig. 2. The upper panels show the blood flow of the limbs in the control (untransplanted) mouse. The lower panels show the blood flow in a mouse that received hPDMCs. The blood flow of ischemic limbs improved after hPDMC transplantation, whereas such improvement was hardly observed in the control mouse. Fig. 3 summarizes the blood flow changes of ischemic limbs after hPDMC transplantation. Before transplantation the blood flow of ischemic limbs was 0.211 ± 0.008 ($n = 15$) (mean \pm SE) of the blood flow of non-ischemic limbs in the hPDMC-




Fig. 2. Improvement of hindlimb ischemia by hPDMC transplantation in NOD/Shi-scid mice. The upper panels (control) show the blood flow changes of limbs in a control NOD/Shi-scid mouse. The middle panels (hPDMCs) show the blood flow changes in a mouse that received transplanted hPDMCs in the ischemic limb. The lower panels (PBMCs) show the blood flow changes in a mouse that received transplanted PBMCs in the ischemic limb. Data at days 0, 7, and 14 are shown.




Fig. 3. The blood flows of ischemic limbs before and after hPDMC transplantation are shown (mean \pm SE). The ordinate indicates the blood flow of the ischemic limb as compared to that of the unaffected limb. "hPDMCs" (circles) indicates data from mice transplanted with hPDMCs, "control" (triangles) indicates data from mice without any injection, "DMEM" (inverted triangles) indicates data from mice injected only with DMEM, and "PBMCs" (squares) indicates data from mice injected with PBMCs. Data are expressed as means \pm SE. * $p < 0.05$ and ** $p < 0.05$ as compared to "control" and "DMEM" group.

transplanted group. It was 0.228 ± 0.012 ($n = 13$) in the untransplanted group, 0.220 ± 0.013 ($n = 14$) in the medium-injected group, and 0.207 ± 0.009 ($n = 15$) in the PBMC-transplanted group. Seven days after treatment, the blood flow of ischemic limbs increased to 0.511 ± 0.056 of the blood flow of the non-ischemic limbs in the hPDMC-transplanted group. It was 0.346 ± 0.028 in the untransplanted group, 0.313 ± 0.017 in the medium-injected group, and 0.400 ± 0.045 in the PBMC-transplanted group. Fourteen days after treatment, the blood flow of ischemic limbs was 0.495 ± 0.048 of the blood flow of the non-ischemic limbs in the hPDMC-transplanted group. It was 0.367 ± 0.050 in the untransplanted group, 0.376 ± 0.048 in the medium-injected group, and 0.450 ± 0.054 in the PBMC-transplanted group. The ischemia in the hPDMC-transplanted group was significantly improved at day 7 and day 14 ($p < 0.05$ as compared to untransplanted group and medium-injected group). These results indicate that hPDMC transplantation is an effective treatment in the hindlimb

ischemia model of NOD/Shi-scid mice. The ischemia in the PBMC-transplanted group appeared to be improved but the increase of the blood flow was not statistically significant.

Immunohistochemical analysis of new vessel formation

Upper panels of Fig. 4 show representative photographs of ischemic muscles stained with hematoxylin and eosin (HE). Lower panels show the immunohistochemical staining using anti-factor VIII antibody. Endothelial cells and capillaries are clearly observed with this staining (arrows). The hPDMC-transplanted group (left) showed a larger number of endothelial cells and capillary formation than the control group and the DMEM group (middle and right). The numbers of capillaries and muscle fibers were counted in 10 randomly selected sections of muscles from three mice in each group (under 200× magnification) and the mean was calculated. Capillary/muscle fiber ratios for the hPDMC-transplanted mice, medium-injected mice, and uninjected mice were 0.136 ± 0.008 (mean \pm SE) ($n = 3$), 0.052 ± 0.001 , and 0.053 ± 0.003 , respectively (Fig. 5). The capillary/muscle fiber ratio of the hPDMC-transplanted mice was significantly greater than those of the medium-injected mice ($p < 0.01$) and the uninjected mice ($p < 0.01$), indicating that the angiogenesis was promoted by hPDMC transplantation. These results correspond to the results of the blood flow analysis described above.

Detection of hVEGF by real-time RT-PCR

To determine the length of time that transplanted hPDMCs produce hVEGF in NOD/Shi-scid mice, we used real-time RT-PCR to detect hVEGF mRNA expression in muscle (Fig. 6). hVEGF mRNA expression was normalized by setting the mean mRNA expression 3 h after hPDMC transplantation to be 1.0 (1.0 ± 0.40)




Fig. 4. Immunohistochemical analysis of new vessel formation. Representative photographs of limb muscle stained with HE (upper panels) and with anti-factor VIII antibody (F-VIII) (lower panels) are shown. Arrows indicate the capillary or endothelium. “hPDMCs” indicates a mouse transplanted with hPDMCs, “control” indicates a mouse without any injection, and “DMEM” indicates a mouse injected only with DMEM. Bar = 50 μ m.




Fig. 5. Capillary/muscle fiber ratio of ischemic muscles. Ten samples in each animal were randomly selected, and the capillaries and muscle fibers were counted. The ordinate indicates the capillary/muscle fiber ratio. “hPDMCs” indicates a mouse transplanted with hPDMCs, “control” indicates a mouse without any injection, and “DMEM” indicates a mouse injected only with DMEM. Data are expressed as means \pm SE.

(mean \pm SE, $n = 3$). After 2 days, hVEGF mRNA expression was about 0.11 ± 0.017 of the expression at day 0. hVEGF mRNA expression was still observed after 7 days (0.013 ± 0.00086 of the expression at day 0). Only very weak signal was detected in the control muscle without hPDMC transplantation ($3.56 \times 10^{-4} \pm 5.4 \times 10^{-5}$). These results indicate that transplanted hPDMCs were alive and kept producing hVEGF at least for 7 days at the site of injection.

Discussion

The results of the present study revealed that hPDMCs produced hVEGF. The amount of hVEGF secreted from hPDMCs was similar to the amount produced by HeLa cells, which are malignant cells that form tumor vessels. hVEGF production was not detected in hUVECs. hVEGF production in PBMCs was very small, consistent with a previous report by Salven et al. [27]. We detected VEGF-A mRNA in this study. However, further study is necessary to confirm the expression pattern of other VEGF isoforms. A hUVEC proliferation assay confirmed that the hVEGF secreted by hPDMCs was biologically active. The fact that the biological activity of hPDMC conditioned medium




Fig. 6. Detection of hVEGF in mouse muscle by real-time RT-PCR. The ordinate indicates the hVEGF mRNA expression level in the limb muscle of NOD/Shi-scid mouse. The mean hVEGF expression level 3 h after hPDMCs transplantation was determined as 1.0, and the other expression levels were normalized. Data are expressed as means \pm SE ($n = 3$). The inset in the figure shows the data at day 7 and those of the control in an amplified vertical scale.

was stronger than that predicted by ELISA and that anti-VEGF blocking antibody only partially blocked the bioactivity of hPDMC conditioned medium suggests other factor(s) than hVEGF are also involved in the stimulation of hUVEC proliferation. Further study is needed to identify the factor(s). In an animal model of hindlimb ischemia, transplantation of hPDMCs significantly improved the blood flow of affected limbs. Histological examination demonstrated that the new blood vessel formation in treated mice was more abundant than that in control mice. Real-time RT-PCR showed that transplanted hPDMCs produced hVEGF for at least 7 days in NOD/Shi-scid mice. These results suggest that cell therapy using hPDMCs may be a useful treatment for ischemic diseases. We postulated that the mechanism of angiogenesis enhanced by hPDMC-transplantation was the local production of pro-angiogenic growth factors or cytokines. However, there is also a possibility that transplanted hPDMCs differentiated into endothelial cells. Further studies are necessary to elucidate it.

Recently much attention has been paid to the benefits of using placenta as a source of cells for tissue engineering [28]. There is no risk to donors, and the placenta is a large tissue from which many cells can be harvested. The risk of abnormal transformation or proliferation can be minimized if placentae from full-term deliveries are

used. Immature placenta or hydatidiform moles should not be used due to the risk of abnormal transformation or proliferation. hPDMCs used in this study were positive to CD105 and CD73 antibodies, and negative to CD21 and CD23 antibodies. Therefore, hPDMCs are different from fibroblasts, which are CD105 and CD73 negative, and they are also different from human decidual stroma cells described by Oliver et al. [29], which are positive to CD21 and CD23. hPDMCs are also different from CD86-positive Hofbauer cells, which are derived from macrophage and produce VEGF [30], because CD86 and CD14 were negative in hPDMCs. Clark et al. [31] found hVEGF mRNA expression in placenta using in situ hybridization. They also reported that PlGF is detected in villous and extravillous trophoblasts, whereas hVEGF is solely detected in maternal glands. This finding coincides with that the hPDMCs used in this study are of maternal origin. Further characterization of hPDMCs remains to be seen.

Pro-angiogenic therapies previously reported are direct injection of angiogenic factors, expression of angiogenic genes by plasmid or virus vectors, and cell therapy [2–5,11,13–18]. Administration of angiogenic factors, such as VEGF or FGF-2, has been reported to be an effective treatment for ischemia. However, there are controversial reports about its efficacy, and there are also reports about serious adverse events [7,8]. In animal models angiogenic factors are applied using slow-release polymers [9,10], but the safety of these beads has not been proven in humans. Without a slow-release device, angiogenic factors injected into skin or muscle are easily absorbed into systemic circulation and it is difficult to stably apply angiogenic factors at local lesions. Gene expression of angiogenic factors in ischemic muscles can overcome the problem of local administration. However, gene expression is not currently well regulated, which causes unfavorable adverse events [7,8]. Additionally, a death has been reported after in vivo application of virus vectors into a human [32]. The clinical efficacy of cell therapy for ischemic diseases using autologous endothelial progenitor cells or mononuclear cells has been reported [19]. Because apheresis is required, facilities in which these cell therapies can be performed are limited. There are also patient safety problems with the cell collection procedures. Thus, an ideal therapy for ischemic diseases has not yet been established.

hPDMCs used in this study are derived from normal placentae at full-term deliveries. Abundant vessels with normal architecture are formed in the placenta to exchange nutrients between mother and fetus. The present study shows that hPDMCs produce a large amount of bioactive hVEGF without any gene modification. Transplantation of hPDMCs to NOD/Shi-scid mice significantly improved the blood flow of ischemic limbs. If a human clinical study is considered, HLA information

may be necessary for allogeneic hPDMC transplantation. Real-time RT-PCR revealed that hVEGF was expressed in NOD/Shi-scid mice for at least 7 days after transplantation. Although the length of time that transplanted hPDMCs would survive in humans is unknown, it is improbable that they would be acutely rejected if HLA matching is performed. Because immunosuppressants would not be used in human clinical studies, transplanted hPDMCs would eventually be rejected after local administration of hVEGF, which supports the safety of this therapy.

Iba et al. [16] have reported that transplantation of peripheral blood mononuclear cells improved blood flow in ischemic limbs. However, we did not observe significant improvement of ischemia in the PBMC-transplanted group, which may be ascribed to the difference of experimental conditions although the exact reason is unknown. VEGF in combination with angiopoietin induces angiogenesis more effectively and with fewer adverse events than VEGF alone [11]. Similarly, the combination of platelet-derived growth factor (PDGF)-BB and FGF-2 induces functional and stable vessels much more effectively than a single angiogenic factor [10]. We previously reported that adenovirus and adeno-associated virus efficiently mediate gene expression in hPDMCs [33]. By transducing the cells with a gene (other than hVEGF) which promotes angiogenesis, hPDMCs may become more potent inducers of angiogenesis. Safety is a very important issue in gene therapy. Because the transduction of hPDMCs is done *ex vivo*, there is little possibility of vector contaminating patients. The safety of this treatment may be enhanced by irradiating the transduced cells before transplantation. Thus, it is possible that cell therapy for ischemia using hPDMCs can be improved in the future.

Acknowledgments

We are grateful to Dr. Hirofumi Hamada (Sapporo Medical University) for advice on animal experiments. We thank Ms. Kaori Sato for technical assistance.

References

- [1] J. Folkman, Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis, *N. Engl. J. Med.* 333 (1995) 1757–1763.
- [2] S.B. Freedman, J.M. Isner, Therapeutic angiogenesis for coronary artery disease, *Ann. Intern. Med.* 136 (2002) 54–71.
- [3] J.M. Isner, Myocardial gene therapy, *Nature* 415 (2002) 234–239.
- [4] J. Waltenberger, Modulation of growth factor action: implications for the treatment of cardiovascular diseases, *Circulation* 96 (1997) 4083–4094.
- [5] N. Ohara, H. Koyama, T. Miyata, H. Hamada, S.I. Miyatake, M. Akimoto, H. Shigematsu, Adenovirus-mediated *ex vivo* gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia, *Gene Ther.* 8 (2001) 837–845.
- [6] R. Morishita, S. Nakamura, S. Hayashi, Y. Taniyama, A. Moriguchi, T. Nagano, M. Taiji, H. Noguchi, S. Takeshita, K. Matsumoto, T. Nakamura, J. Higaki, T. Ogihara, Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy, *Hypertension* 33 (1999) 1379–1384.
- [7] P. Carmeliet, VEGF gene therapy: stimulating angiogenesis or angioma-genesis?, *Nat. Med.* 6 (2000) 1102–1103.
- [8] R.J. Lee, M.L. Springer, W.E. Blanco-Bose, R. Shaw, P.C. Ursell, H.M. Blau, VEGF gene delivery to myocardium: deleterious effects of unregulated expression, *Circulation* 102 (2000) 898–901.
- [9] T.P. Richardson, M.C. Peters, A.B. Ennett, D.J. Mooney, Polymeric system for dual growth factor delivery, *Nat. Biotechnol.* 19 (2001) 1029–1034.
- [10] R. Cao, E. Brakenhielm, R. Pawliuk, D. Wariaro, M.J. Post, E. Wahlberg, P. Leboulch, Y. Cao, Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2, *Nat. Med.* 9 (2003) 604–613.
- [11] A. Yamauchi, Y. Ito, M. Morikawa, M. Kobune, J. Huang, K. Sasaki, K. Takahashi, K. Nakamura, H. Dehari, Y. Niitsu, T. Abe, H. Hamada, Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model, *J. Gene Med.* 5 (2003) 994–1004.
- [12] C.R. Ozawa, A. Banfi, N.L. Glazer, G. Thurston, M.L. Springer, P.E. Kraft, D.M. McDonald, H.M. Blau, Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis, *J. Clin. Invest.* 113 (2004) 516–527.
- [13] A. Kawamoto, H.C. Gwon, H. Iwaguro, J.I. Yamaguchi, S. Uchida, H. Masuda, M. Silver, H. Ma, M. Kearney, J.M. Isner, T. Asahara, Therapeutic potential of *ex vivo* expanded endothelial progenitor cells for myocardial ischemia, *Circulation* 103 (2001) 634–637.
- [14] A. Kawamoto, T. Tkebuchava, J. Yamaguchi, H. Nishimura, Y.S. Yoon, C. Milliken, S. Uchida, O. Masuo, H. Iwaguro, H. Ma, A. Hanley, M. Silver, M. Kearney, D.W. Losordo, J.M. Isner, T. Asahara, Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia, *Circulation* 107 (2003) 461–468.
- [15] T. Murohara, H. Ikeda, J. Duan, S. Shintani, K. Sasaki, H. Eguchi, I. Onitsuka, K. Matsui, T. Imaizumi, Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization, *J. Clin. Invest.* 105 (2000) 1527–1536.
- [16] O. Iba, H. Matsubara, Y. Nozawa, S. Fujiyama, K. Amano, Y. Mori, H. Kojima, T. Iwasaka, Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs, *Circulation* 106 (2002) 2019–2025.
- [17] H. Kamihata, H. Matsubara, T. Nishiue, S. Fujiyama, Y. Tsutsumi, R. Ozono, H. Masaki, Y. Mori, O. Iba, E. Tateishi, A. Kosaki, S. Shintani, T. Murohara, T. Imaizumi, T. Iwasaka, Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines, *Circulation* 104 (2001) 1046–1052.
- [18] S. Shintani, T. Murohara, H. Ikeda, T. Ueno, K. Sasaki, J. Duan, T. Imaizumi, Augmentation of postnatal neovascularization with autologous bone marrow transplantation, *Circulation* 103 (2001) 897–903.
- [19] E. Tateishi-Yuyama, H. Matsubara, T. Murohara, U. Ikeda, S. Shintani, H. Masaki, K. Amano, Y. Kishimoto, K. Yoshimoto, H. Akashi, K. Shimada, T. Iwasaka, T. Imaizumi, Therapeutic angiogenesis using cell transplantation study, therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial, *Lancet* 360 (2002) 427–435.

- [20] P. Rubinstein, C. Carrier, A. Scaradavou, J. Kurtzberg, J. Adamson, A.R. Migliaccio, R.L. Berkowitz, M. Cabbad, N.L. Dobrila, P.E. Taylor, R.E. Rosenfield, C.E. Stevens, Outcomes among 562 recipients of placental–blood transplants from unrelated donors, *N. Engl. J. Med.* 339 (1998) 1565–1577.
- [21] N. Watanabe et al., Multilineage potential of human placenta-derived mesenchymal cells, *Blood* 100 (Suppl. 1) (2002) 517a.
- [22] G. Conn, D.D. Soderman, M.T. Schaeffer, M. Wile, V.B. Hatcher, K.A. Thomas, Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line, *Proc. Natl. Acad. Sci. USA* 87 (1990) 1323–1327.
- [23] J.S. Silvestre, Z. Mallat, M. Duriez, R. Tamarat, M.F. Bureau, D. Scherman, N. Duverger, D. Branellec, A. Tedgui, B.I. Levy, Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb, *Circ. Res.* 87 (2000) 448–452.
- [24] H. Yoshino, T. Ueda, M. Kawahata, K. Kobayashi, Y. Ebihara, A. Manabe, R. Tanaka, M. Ito, S. Asano, T. Nakahata, K. Tsuji, Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice, *Bone Marrow Transplant* 26 (2000) 1211–1216.
- [25] Y. Tsutsumi, H. Matsubara, N. Ohkubo, Y. Mori, Y. Nozawa, S. Murasawa, K. Kijima, K. Maruyama, H. Masaki, Y. Moriguchi, Y. Shibasaki, H. Kamihata, M. Inada, T. Iwasaka, Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression, *Circ. Res.* 83 (1998) 1035–1046.
- [26] T. Sanchez-Elsner, L.M. Botella, B. Velasco, A. Corbi, L. Attisano, C. Bernabeu, Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression, *J. Biol. Chem.* 276 (2001) 38527–38535.
- [27] P. Salven, K. Hattori, B. Heissig, S. Rafii, Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion, *FASEB J.* 16 (2002) 1471–1473.
- [28] A. Kaviani, T.E. Perry, C.M. Barnes, J.T. Oh, M.M. Ziegler, S.J. Fishman, D.O. Fauza, The placenta as a cell source in fetal tissue engineering, *J. Pediatr. Surg.* 37 (2002) 995–999, discussion 995–999.
- [29] C. Oliver, N. Cowdrey, A.C. Abadia-Molina, E.G. Olivares, Antigen phenotype of cultured decidual stromal cells of human term decidua, *J. Reprod. Immunol.* 45 (1999) 19–30.
- [30] S. Khan, H. Katabuchi, M. Araki, R. Nishimura, H. Okamura, Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro, *Biol. Reprod.* 62 (2000) 1075–1083.
- [31] D.E. Clark, S.K. Smith, D. Licence, A.L. Evans, D.S. Charnock-Jones, Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation, *J. Endocrinol.* 159 (1998) 459–467.
- [32] S. Lehrman, Virus treatment questioned after gene therapy death, *Nature* 401 (1999) 517–518.
- [33] X. Zhang, T. Nakaoka, T. Nishishita, N. Watanabe, K. Igura, K. Shinomiya, T.A. Takahashi, N. Yamashita, Efficient adeno-associated virus-mediated gene expression in human placenta-derived mesenchymal cells, *Microbiol. Immunol.* 47 (2003) 109–116.